Last reviewed · How we verify
rFVIIa
rFVIIa, marketed by Fondazione IRCCS Policlinico San Matteo di Pavia, holds a niche position in the hemostatic agents market. The drug's key strength lies in its unique mechanism of action, which is protected by a key composition patent expiring in 2028. The primary risk to the drug's market position is the lack of significant revenue data, which may impact investor confidence and market expansion efforts.
At a glance
| Generic name | rFVIIa |
|---|---|
| Also known as | Experimental, Novo 7, eptacog alpha (activated), Niastase RT, Recombinant activated factor VII |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India (PHASE4)
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 (PHASE3)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (PHASE3)
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (PHASE4)
- Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rFVIIa CI brief — competitive landscape report
- rFVIIa updates RSS · CI watch RSS
- Fondazione IRCCS Policlinico San Matteo di Pavia portfolio CI